Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy (Q39901974)

15 September 2017

Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy (English)

1 reference

15 September 2017

Jeong Hun Kim

1

1 reference

15 September 2017

Jin Hyoung Kim

2

1 reference

15 September 2017

Young Suk Yu

3

1 reference

15 September 2017

Chang Sik Cho

4

1 reference

15 September 2017

Kyu-Won Kim

5

1 reference

15 September 2017

24 December 2008

1 reference

Journal of Cerebral Blood Flow & Metabolism

15 September 2017

1 reference

15 September 2017

29

1 reference

15 September 2017

621-628

1 reference

15 September 2017

3

1 reference

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

15 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

Molecular mechanisms of vascular permeability in diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

AKAP12 regulates human blood-retinal barrier formation by downregulation of hypoxia-inducible factor-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

How the diabetic eye loses vision.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

The role of clusterin in retinal development and free radical damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

Early cellular and molecular changes induced by diabetes in the retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-kappaB pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

Suppression of ocular inflammation in endotoxin-induced uveitis by blocking the angiotensin II type 1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

Quantitative receptor autoradiographic analysis for angiotensin II receptors in bovine retinal microvessels: quantitation with radioluminography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

Pathophysiological consequences of VEGF-induced vascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

Perindopril: possible use in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

7 January 2021

Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice.

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

7 January 2021

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

1 reference

7 January 2021

The role of clusterin in in vitro ischemia of human retinal endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

7 January 2021

Retinal neovascularization is prevented by blockade of the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

7 January 2021

Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

7 January 2021

Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways.

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

7 January 2021

Increased serum angiotensin converting enzyme activity in type I insulin-dependent diabetes mellitus: its relation to metabolic control and diabetic complications

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.2008.154

7 January 2021

Identifiers

DOI

10.1038/JCBFM.2008.154

1 reference

15 September 2017

1 reference